Methotrexate with thymidine, inosine, and allopurinol rescue: a phase i clinical study
Dady, P.J.; Taylor, G.A.; Muindi, J.F.; Calvert, A.H.; Smith, I.E.; Smyth, J.F.; Harrap, K.R.
Cancer Treatment Reports 65(Suppl 1): 37-43
1981
ISSN/ISBN: 0361-5960 PMID: 7326664 Document Number: 176247
A phase I clinical study of a combination of thymidine (TdR), inosine (IR), and allopurinol used as rescue from 24-hour infusions of methotrexate (MTX) was undertaken following animal studies that had shown a better preservation of antitumor activity with this system than with folinic acid. TdR and IR were given in the dose ratio 5:1 by weight throughout. Rescue from MTX, 400 mg/m2, could be achieved with a TdR dose in the combination of 1 g/m2/24 hours. This same rescue was also effective when the MTX dose was increased to 800 mg/m2, but only partly effective at an MTX dose of 1.5 g/m2. It was not necessary to raise the levels of circulating nucleosides significantly above normal to achieve rescue. MTX-related skin lesions occurred more frequently than might be expected with the MTX dose used.